Pharma & Life Sciences SMB (51-200 employees)

Pharmacovigilance Specialist at SMB

High Conscientiousness and Openness to detect safety signals, manage PSURs, and keep the PV system regulatory compliant.

In SMB pharma, quality and compliance are the license to operate

The development pipeline is the company's valuation and main asset

The relationship with local health authorities is capital built over years

Generic profile Startup (1-50 employees) Enterprise (201-1000 employees) Global (1001+ employees)

Ideal OCEAN+ Profile

Ideal range

Openness

73 87

At SMBs (51-200 employees), analytical ability to detect emerging signals in safety data, interpret trends, and propose complex risk-benefit assessments

Conscientiousness

78 90

At SMBs (51-200 employees), rigor in case follow-up, generating periodic reports, keeping SOPs current, and meeting reporting obligations to agencies

Extraversion

55 71

At SMBs (51-200 employees), presenting safety findings to internal committees and regulatory agencies; communicating PV system updates across the organization

Agreeableness

55 70

At SMBs (51-200 employees), collaboration with medical affairs, regulatory, clinical, and legal for comprehensive management of product safety obligations

Emotional Stability

75 89

At SMBs (51-200 employees), managing stress from critical safety signals that require fast regulatory response and decisions that affect product availability

Structure & Rhythm

75 88

At SMBs (51-200 employees), the pharmacovigilance specialist sustains the periodic reporting cycle (PSUR/PBRER), signal management, and risk-evaluation SOPs; process adherence is what makes the safety dossier defensible under inspection

Strengths and Red Flags

Strengths

Detection and evaluation of emerging safety signals using robust statistical methodologies
Management of PSURs, PADERs, and benefit-risk reports with high documentation quality
Managing development pipelines balancing innovation with commercial viability
GMP and regulatory compliance with limited internal quality teams

Red Flags

Mechanical case processing without a signal-detection mindset, turning PV into a bureaucratic process
Missed reporting deadlines that expose the company to regulatory action
Difficulty maintaining compliance with limited quality resources
Resists outsourcing activities it can't perform internally

Interview Questions

Have you ever detected an emerging safety signal? Describe what data alerted you, what evaluation methodology you used, and what regulatory action followed.

Evaluates: Analytical Openness and rigor in signal detection and evaluation

How many PSURs or PADERs have you prepared? Describe your process for generating the Benefit-Risk Summary and the most common errors you avoid.

Evaluates: Conscientiousness and technical mastery of periodic safety reporting

How did you maintain GMP compliance with limited quality teams?

Evaluates: Conscientiousness and efficiency in quality management

How did you balance innovation with commercial viability in your pipeline?

Evaluates: Balance between scientific rigor and business pragmatism